Oxford BioDynamics (LON: OBD) says Pfizer has published information on its use of EpiSwitch biomarkers as a liquid biopsy in evaluating tumours and treatment outcomes for the JAVELIN bladder 100 trial. The EpiSwitch test can determine whether a tumour has high or low immune activity. This confirmation of efficacy will help to grow EpiSwitch sales. The share price jumped 101.9% to 0.525p, the highest level since the beginning of March.
Digital loyalty and promotions platform operator Eagle Eye (LON: EYE) did better than anticipated in the year to June 2025 with revenues 1% higher at £48.2m and EBITDA is 9% ahead at £12.2m. A recent contract loss led to the downgrading of 2025-26 forecasts. Annualised recurring revenue are £32m after that contract loss. New business is being won, and profitability should be rebuilt in 2026-27. A £1m share buyback is planned. The share price recovered 9.52% to 230p.
TV programme producer Zinc Media (LON: ZIN) has secured and due revenues of £35m, so far this year, up from £27m at the same point last year. Simplifying the group structure has reduced annual overheads by £300,000. Net cash was £700,000 at the end of June 2025. The share price improved 6.57% to 73p.
Sold state batterie developer Ilika (LON: IKA) is receiving £1.25m in grants for the manufacturing of the first Goliath A-Sample batteries for the automotive industry. This part of a programme named PRIMED, which will help with the industrialisation of production. The share price rose 7.69% to 42p.
FALLERS
Womenswear retailer Sosandar (LON: SOS) reported a lower than expected underlying pre-tax profit of £200,000 in the year to March 2025, because of stock adjustments. There was a loss in the previous year. Revenues fell from £46.3m to £37.1m as the move to reduce online price promotion activity hit sales but improved margins. Six stores have been opened. The four store in market town are trading well, but the two in shopping centre have not been as successful. Online sales have benefited in the areas where there are stores. No new stores are planned for this year. There is a strong start to this financial year with first quarter revenue 15% ahead. Initial licensing revenues will come through later in the year. Net cash is £7.3m. The share price declined 21.9% to 6.25p.
Data analytic technology developer Cirata (LON: CRTA) increased first half bookings by 58%, but the second quarter figure was down, and the cash outflow is slowing. The annualised cash overhead is being reduced to $12m-$13m. The DevOps assets are being sold for up to $3.5m. The share price decreased 18.3% to 23.7p.
Oil and gas producers Arrow Exploration (LON: AXL) has drilled three wells on the 50%-owned Tapir block in Colombia. These are already producing. Net production is 4.6-4.8mboe/day, so the new production has more than offset declines elsewhere. Cash was $13.5m at the beginning of July. Cash was $6.1m at the end of June 2025. There should be no requirement for a fundraising this year. The share price slipped 7.14% to 16.25p.
Embedded computer products manufacturer Concurrent Technologies (LON: CNC) continues to improve revenues and profit. Interim revenues are 27% higher at £21.3m, while pre-tax profit edges up from £2.3m to £2.4m. The second half has started positively, but there is uncertainty about US demand. The share price fell 11.9% to 174p.